The polyomaviruses WUPyV and KIPyV: a retrospective quantitative analysis in patients undergoing hematopoietic stem cell transplantation

Table 1 Characteristics of the 5 hematopoietic stem cell transplantation (HSCT) patients presenting WUPyV or KIPyV

Virus	Patient	Transplant type	GvHD	Antiviral therapy	Co-infecting viruses in RTS	Co-infecting viruses in stool	Co-infecting viruses in further samples
KIPyV (adult patients)	1	Double Cord-Blood- Transplantation	Chronic (skin, gut - max. IV°)	Cidofovir (days +121 to +272)	HHV6, HSV	HHV6	HHV6 (leukocytes), BKV, HHV6 (urine)
	2	Allogeneic PBSCT	Chronic ( skin, gut - max. IV°)	Cidofovir, Ribavirin ( days +118 to +176)	EBV, HHV6, HSV	Adenovirus, EBV	EBV, HHV6, Adenovirus (leukocytes)
	3	Allogeneic BMT	Acute (skin - max. II°)	Foscarnet ( days +19 to +55), Cidofovir ( days +55 to +138)	HHV6, EBV	none	EBV (leukocytes)
	4	Allogeneic PBSCT	Acute (gut - max. III°)	none	HHV6	HHV6	HHV6, EBV (leukocytes)
WUPyV (infant)	5	Allogeneic PBSCT	Chronic (pre-PBSCT: skin, gut, hematopoietic system - max. III°)	Cidofovir ( days +17 to +58)	HHV6, Adenovirus, HHV7, HSV	Norovirus, Adenovirus, HHV6	HHV6 (urine)

Clinical data summary for the HSCT patients that tested positive for WUPyV and KIPyV including detected co-infecting viruses throughout the observation period and antiviral therapy; Antiviral therapy: all patients received prophylactic Acyclovir therapy. Further antiviral therapy is depicted with time-points (day 0: day of HSCT). Co-infecting viruses in RTS, stool and further samples in order of detection frequency. GvHD: Graft versus Host Disease; RTS: respiratory tract samples, PBSCT: peripheral blood stem cell transplantation.

ISSN: 1743-422X